SEC Form 4 · accession 0001246360-15-001571

NxStage Medical, Inc. · NXTM

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Executive Officer · Director

Period of report

Mar 17, 2015

Accepted (ET)

Mar 19, 2015 · 4:56 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001333170

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Mar 17, 2015	M	10,000	$2.11	A	886,756	D
Common Stock^F2	Mar 17, 2015	S	10,000	$17.36	D	876,756	D
Common Stock	Mar 18, 2015	M	10,000	$2.11	A	886,756	D
Common Stock^F3	Mar 18, 2015	S	10,000	$17.43	D	876,756	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)	$2.11	Mar 17, 2015	M	10,000	D	Apr 5, 2009	Mar 4, 2016	Common Stock	10,000	179,274	D
Stock Option (Right to Buy)	$2.11	Mar 18, 2015	M	10,000	D	Apr 5, 2009	Mar 4, 2016	Common Stock	10,000	169,274	D

F1This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2014.
F2This represents the weighted average price for shares sold in multiple transactions at prices ranging from $16.83 to $17.48, inclusive. Full information regarding the number of shares sold at each separate price within the range will be provided to NxStage Medical, Inc., any security holder of NxStage Medical, Inc. or the staff of the Securities and Exchange Commission, upon request.
F3This represents the weighted average price for shares sold in multiple transactions at prices ranging from $17.29 to $17.56, inclusive. Full information regarding the number of shares sold at each separate price within the range will be provided to NxStage Medical, Inc., any security holder of NxStage Medical, Inc. or the staff of the Securities and Exchange Commission, upon request.